ERB-041

PreclinicalSmall molecule

Pfizer

ERB-041 is one of 16 small molecule programs targeting Interstitial Cystitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial CystitisActive, not recruiting

Interstitial CystitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Interstitial Cystitis

#DrugCompanyPhaseTrials

Toradol

Roche

Approved

1 2

Elavil

Revia

Cellcept

Pitocin

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 7

Neurontin

VViatris Specialty LLC

Approved

—8

Kenalog

BBausch Health Americas, Inc.

Elmiron

1 10

Neovasculgen

AArtgen Biotech

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometriosis2 trials

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

Completed· Pfizer logo

Pfizer·Phase 2·NCT00318500·150 enrolled

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

Completed· Pfizer logo

Pfizer·Phase 2·NCT00110487·200 enrolled

Crohn's Disease1 trial

Study Evaluating ERB-041 in Active Crohn's Disease

Completed· Pfizer logo

Pfizer·Phase 1·NCT00245947·22 enrolled

Female1 trial

Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00434187·24 enrolled

Cardiac Repolarization1 trial

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00316459·64 enrolled

Interstitial Cystitis1 trial

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

Withdrawn· Pfizer logo

Pfizer·N/A·NCT00275379

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ERB-041. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ERB-041 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ERB-041. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

ERB-041

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endometriosis2 trials

Crohn's Disease1 trial

Female1 trial

Cardiac Repolarization1 trial

Interstitial Cystitis1 trial

References

Drug Info

Quick Facts

Related News